Results 121 to 130 of about 356,203 (328)

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

TGF-beta 1 induces human alveolar epithelial to mesenchymal cell transition (EMT) [PDF]

, 2005
Background: Fibroblastic foci are characteristic features in lung parenchyma of patients with idiopathic pulmonary fibrosis (IPF). They comprise aggregates of mesenchymal cells which underlie sites of unresolved epithelial injury and are associated with ...
A Atfi, A Desmouliere, A Desmouliere, CM Ewing, D Upadhyay, DA Vesey, DG. Hoyt, DW Powell, DW Powell, DY Rhyu, E Healy, E Piek, EE Moussad, EP Bottinger, F Strutz, G Raghu, GR Grotendorst, HW Yao, J Fan, J Gauldie, J Nightingale, J Yang, JT Allen, JT Allen, K Vleminckx, KA Foster, LH Pan, M Kelly, M Selman, M Selman, M Whitman, N Khalil, N Khalil, N Khalil, NA Bhowmick, NA Wahab, NA Wahab, NA Wahab, P Bonniaud, P Sharmila, PJ Miettinen, PJ Sime, R Derynck, R Kalluri, S Hashimoto, T Maeyama, TE King Jr, TJ Gross, V Mermall, Y Higashimoto, Y Liu   +50 more
core   +4 more sources

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

The integrin-binding defective FGF2 mutants potently suppress FGF2 signalling and angiogenesis. [PDF]

, 2017
We recently found that integrin αvβ3 binds to fibroblast growth factor (FGF)-αvβ31 (FGF1), and that the integrin-binding defective FGF1 mutant (Arg-50 to glutamic acid, R50E) is defective in signalling and antagonistic to FGF1 signalling. R50E suppressed
Hamada, Yoshinosuke, Hatori, Nobuaki, Kawaguchi, Naomasa, Lam, Kit S, Matsuura, Nariaki, Mori, Seiji, Shih, Tsung-Chieh, Takada, Yoko K, Takada, Yoshikazu, Wu, Chun-Yi, Yamamoto, Hirofumi   +10 more
core   +2 more sources

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

The roles of FGFR3 and c-MYC in urothelial bladder cancer

Discover Oncology
Bladder cancer is one of the most frequently occurring cancers worldwide. At diagnosis, 75% of urothelial bladder cancer cases have non-muscle invasive bladder cancer while 25% have muscle invasive or metastatic disease.
Dereje E. Bogale
doaj   +1 more source

Identifying Fibroblast Growth Factor Receptor 3 as a Mediator of Periosteal Osteochondral Differentiation through the Construction of microRNA-Based Interaction Networks. [PDF]

Biology (Basel), 2023
Wells LM, Roberts HC, Luyten FP, Roberts SJ.   +3 more
europepmc   +1 more source

Comparison of Non-human Primate versus Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Treatment of Myocardial Infarction. [PDF]

, 2018
Non-human primates (NHPs) can serve as a human-like model to study cell therapy using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). However, whether the efficacy of NHP and human iPSC-CMs is mechanistically similar remains unknown.
Aguirre, Aitor, Chen, Haodong, Chour, Tony, Holmström, Alexandra, Itzhaki, Ilanit, Jain, Mohit, Kim, Youngkyun, Lehmann, Kim, Ndoye, Babacar C, Neofytou, Evgenios, Qin, Xulei, Shukla, Praveen, Wu, Joseph C, Xiao, Dan, Yang, Huaxiao, Zhang, Joe Z, Zhao, Mingtao, Zhao, Xin, Zhuge, Yan, Zimmermann, Wolfram-Hubertus   +19 more
core   +3 more sources

Supplementary Figure 4 from Signal Transducers and Activators of Transcription-3 Binding to the Fibroblast Growth Factor Receptor Is Activated by Receptor Amplification [PDF]

, 2023
Anna A. Dudka, Steve M. M. Sweet, John K. Heath   +2 more
openalex   +1 more source

Genomic Organization of the Mouse Fibroblast Growth Factor Receptor 3 (Fgfr3) Gene

Genomics, 1995
The fibroblast growth factor receptor 3 (Fgfr3) protein is a tyrosine kinase receptor involved in the signal transduction of various fibroblast growth factors. Recent studies suggest its important role in normal development. In humans, mutation in Fgfr3 is responsible for growth disorders such as achondroplasia, hypoachondroplasia, and thanatophoric ...
A V, Perez-Castro, J, Wilson, M R, Altherr   +2 more
openaire   +2 more sources